ViiV Healthcare, GlaxoSmithKline Plc’s HIV unit, said on Thursday it started an African study to evaluate long-acting injectable drug for the prevention of HIV infection in sexually active women.
ViiV Healthcare said in a statement that the cabotegravir study seeks to enroll 3,200 women aged 18 to 45 years from sub-Saharan African countries,.
The “HPTN” 084 Phase III study will evaluate injections given every two months, ViiV Healthcare said.
The company said that the study is being conducted through a public-private funding by ViiV Healthcare, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the Bill and Melinda Gates Foundation.
Viiv Healthcare in 2016 had started a large study on HIV-uninfected men and transgender women who have sex with men to test an experimental long-acting injection for preventing the virus that causes AIDS. (Reuters/NAN)